van Dijk E, et al. - Researchers intended to validate the significant correlation of losses of chromosomes 5q34, 17q12, and 18q11.2-q12.1 with progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab, a finding in the CAIRO2 clinical trial. They also sought validation for the non-existence of such a correlation in patients who did not receive bevacizumab, as shown in the CAIRO trial. They concluded that in patients receiving bevacizumab, the loss of chromosome 18q11.2-q12.1 was consistently predictive for prolonged PFS. They also found that the predictive value of this loss was substantiated by a significant gain in overall survival and overall response rate.